Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
Promising pre-clinical results for Poolbeg Pharma’s POLB 001
Poolbeg Pharma’s new treatment, POLB 001, shows promise in reducing cytokine release syndrome, a common side effect of cancer immunotherapies. Learn more here.